Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jun 21, 2026
Trulieve Cannabis (TRLV) Rallies +42.6% on NYSE Uplisting and $50 Million Buyback

Trulieve Cannabis (TRLV) Rallies +42.6% on NYSE Uplisting and $50 Million Buyback

Key Takeaways

  • TRLV surged approximately 42.6% over the last 30 days, driven by a historic NYSE uplisting and a $50 million share repurchase program.
  • The stock rallied roughly 79% during the most recent quarter, reflecting improving fundamentals and regulatory tailwinds.
  • Trulieve became the first U.S. cannabis company to list on the New York Stock Exchange, a milestone that significantly boosted investor sentiment and institutional visibility.
  • Q1 2026 results showed $287 million in revenue, a 59% gross margin, and positive net income, underscoring operational strength.
  • Medical marijuana's reclassification to Schedule III removed the 280E tax burden, enhancing free cash flow and profitability.
  • Analyst coverage has turned increasingly bullish, with multiple firms raising price targets and maintaining Buy ratings.

Trulieve Cannabis (TRLV): Company Background and Market Position

Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. The company cultivates, processes, manufactures, and retails a broad portfolio of cannabis products, including flower, edibles, vapes, concentrates, topicals, and accessories. Its brand portfolio spans names such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One. Trulieve operates dispensaries across Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania, with cultivation and processing facilities in several of those states. With approximately 5,000 employees and a market capitalization exceeding $2 billion, Trulieve is one of the largest and most scaled cannabis operators in the United States. Investors follow the stock closely due to its dominant Florida medical market position, expanding hub strategy, and sensitivity to federal cannabis policy developments.

Recent Stock Performance: +42.6% Over 30 Days and +79% for the Quarter

Over the 30-day period ending June 11, 2026, TRLV shares climbed from an adjusted closing price of $8.10 on May 12 to $11.55 on June 11, representing a gain of approximately 42.6%. The rally accelerated sharply in early June following the announcement of the company's NYSE uplisting and share buyback program. Daily trading volumes expanded significantly, with several sessions exceeding 1 million shares traded, reflecting heightened institutional and retail interest.

Zooming out to the quarterly timeframe, the stock's performance is even more striking. From an adjusted close of $6.44 on March 11, 2026, TRLV advanced roughly 79% to the June 11 level. The quarter was characterized by a steady upward grind through April, a brief consolidation in early May, and a powerful breakout in June. This multi-month trend was underpinned by improving financial results, regulatory progress, and growing confidence in the company's strategic direction.

Key Catalysts Behind the 30-Day Surge

The primary catalyst for the 30-day surge was Trulieve's historic transition to the New York Stock Exchange. On June 5, the company announced that its subordinate voting shares would begin trading under the ticker TRLV on June 10, making it the first U.S. cannabis company to list on the NYSE. The uplisting from the OTCQX market represented a major validation for the cannabis sector and opened the door to a broader universe of institutional investors who are restricted from trading over-the-counter securities.

Simultaneously, Trulieve's Board of Directors authorized a share repurchase program of up to $50 million, or approximately 5% of outstanding shares. The buyback announcement signaled management's confidence in the company's intrinsic value and commitment to returning capital to shareholders. These two events, occurring in rapid succession, created a powerful momentum shift that drove the stock sharply higher.

Additional support came from analyst activity. Alliance Global Partners raised its price target and reiterated a Buy rating, while Roth MKM and Haywood also maintained constructive outlooks. The company's Q1 2026 earnings, reported in early May, provided a fundamental backbone for the rally: revenue of $287 million, a 59% gross margin, positive net income of $2 million, and adjusted EBITDA of $100 million demonstrated that Trulieve could deliver profitability at scale. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Broader Drivers Behind Quarterly Gains

The broader quarterly advance was fueled by a confluence of regulatory, operational, and strategic developments. The most significant regulatory shift was the Drug Enforcement Administration's decision to reclassify state-regulated medical marijuana to Schedule III, effectively eliminating the onerous 280E tax provision that had previously prevented cannabis companies from deducting ordinary business expenses. This change immediately improved Trulieve's after-tax cash flow and earnings profile.

Operationally, Trulieve continued to execute its hub strategy, maintaining dominant market share in Florida while selectively expanding in states such as Georgia, Ohio, and Maryland. The company's domestication from British Columbia to Delaware, announced in May, further aligned its corporate structure with U.S. capital markets and removed a technical barrier to the NYSE listing. Throughout the quarter, investor sentiment toward cannabis stocks improved broadly, with peers such as GTBIF, CURA.TO, and VRNO.NE also experiencing upward momentum, though Trulieve's NYSE catalyst set it apart.

Using AI Tools to Analyze Volatile Sectors

As someone who follows fast-moving sectors like cannabis, I frequently review Tickeron’s Trending AI Robots page for a curated view of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies and timeframes. The Trending AI Robots section highlights only those bots demonstrating the most relevant and consistent performance metrics, allowing users to quickly identify strategies aligned with current market conditions. Whether focused on short-term momentum, swing trading, or longer-term trend following, these bots provide a quantitative edge. Exploring the Trending AI Robots page can help traders discover AI-driven approaches tailored to stocks experiencing significant price movements like TRLV.

What Investors Should Watch Next

Looking ahead, several factors will be critical for TRLV's trajectory. The company's next earnings report, estimated for early August 2026, will provide updated visibility on revenue growth, margin trends, and the ongoing impact of 280E tax relief. Investors should monitor any updates on the share repurchase program's execution pace and remaining authorization. Federal cannabis reform discussions, including potential progress on the SAFE Banking Act or broader descheduling efforts, remain a macro catalyst for the entire sector. On the competitive front, Trulieve's ability to defend its Florida market share while scaling newer markets will be closely watched. Additionally, the stock's elevated beta of 1.86 suggests continued sensitivity to broader market volatility and sector rotation. Analyst consensus currently stands at a Strong Buy with a 12-month price target of $21.00, implying significant upside from recent levels, though execution risks and regulatory uncertainty remain inherent to the cannabis industry.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TRLV

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TRLV in upward trend: price rose above 50-day moving average on August 13, 2026

TRLV moved above its 50-day moving average on August 13, 2026 date and that indicates a change from a downward trend to an upward trend. In of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on TRLV as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TRLV just turned positive on August 03, 2026. Looking at past instances where TRLV's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for TRLV crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TRLV broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TRLV entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.868) is normal, around the industry mean (47.296). P/E Ratio (0.000) is within average values for comparable stocks, (94.190). TRLV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.238). TRLV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.927) is also within normal values, averaging (177.127).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.17B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 66%. ALVO experienced the highest price growth at 28%, while INCR experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -11%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 55
SMR Rating: 88
Profit Risk Rating: 82
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
TRLV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Details
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.